Lectin-based biosensors as analytical tools for clinical oncology

Silva, M. Luísa S.

doi:10.1016/j.canlet.2018.08.005

Cited by 24 publications

(14 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distribution of deposited FeOOH@DA‐Lectin nanoparticles delineated the outline of vessel walls. These results demonstrated the first THG angiography in vivo, which is a valuable function for image studies of tumor angiogenesis, biosensors, and nanomedicine pharmacokinetics.…”

Section: Resultsmentioning

confidence: 82%

New Templated Ostwald Ripening Process of Mesostructured FeOOH for Third‐Harmonic Generation Bioimaging

Lee

Hsu

et al. 2019

Small

View full text Add to dashboard Cite

Emerging advances in iron oxide nanoparticles exploit their high magnetization for various applications, such as bioseparation, hyperthermia, and magnetic resonance imaging. In contrast to their excellent magnetic performance, the harmonic generation and luminescence properties of iron oxide nanoparticles have not been thoroughly explored, thus limiting their development as a tool in photomedicine. In this work, a seed/growth‐inspired synthesis is developed combined with primary mineralization and a ligand‐assisted secondary growth strategy to prepare mesostructured α‐FeOOH nanorods (NRs). The sub‐wavelength heterogeneity of the refractive index leads to enhanced third‐harmonic generation (THG) signals under near‐infrared excited wavelengths at 1230 nm. The as‐prepared NRs exhibit an 11‐fold stronger THG intensity compared to bare α‐FeOOH NRs. Using these unique nonlinear optical properties, it is demonstrated that mesostructured α‐FeOOH NRs can serve as biocompatible and nonbleaching contrast agents in THG microscopy for long‐term labeling of cells as well as in angiography in vivo by modifying lectin to enhance the binding efficiency to the glycocalyx layers on the wall of blood vessels. These results provide a new insight into Fe‐based nanoplatforms capable of emitting coherent light as molecular probes in optical microscopy, thus establishing a complementary microscopic imaging method for macroscopic magnetic imaging systems.

show abstract

Section: Resultsmentioning

confidence: 82%

New Templated Ostwald Ripening Process of Mesostructured FeOOH for Third‐Harmonic Generation Bioimaging

Lee

Hsu

et al. 2019

Small

View full text Add to dashboard Cite

show abstract

“…The high-throughput glycoproteomics technology based on the lectin array for screening tumor biomarkers has been recently widely used in the clinical research of malignant tumors ( 27 ). Lectins are biomolecules found in nature with specific affinities toward particular glycan structures, thus forming a relatively strong complex ( 28 , 29 ). Because of this characteristic, lectins have been used in analytical techniques (e.g., lectin affinity chromatography) for the selective capture or separation of certain glycans in complex samples, or used in lectin microarrays for characterizing glycosylation profiles in diverse clinical situations ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis

Kong

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common types of cancer. Despite decades of research efforts, the search for novel biomarkers is still urgently needed for the diagnosis of HCC and the improvement of clinical outcomes. Previous studies of HCC clinical biomarkers have usually focused on serum and urine samples (e.g., serum Alpha-fetoprotein (AFP). However, cellular membrane proteins in lesion tissues are less used in HCC diagnosis. The abnormal expression of membrane glycoproteins in tumor lesions are considered as potential targets for tumor diagnosis and tumor therapies. Here, a lectin array has been employed to screen and identify abnormal glycopatterns and cellular membrane glycans in HCC lesion tissues compared with adjacent non-tumor tissues. We found that there was significantly less expression of Erythrina cristagalli (ECA) lectin binding (Galβ1-3/β1-4) glycans on the cellular membrane of HCC lesion tissues compared with those of adjacent non-tumor tissues. Immunohistochemistry analysis further showed that ECA-binding ability on the membrane proteins of HCC tissues progressively decreased in different tumor-node-metastasis (TNM) stages (stage I to stage III) as the malignancy of liver cancer increased. Receiver operating curve (ROC) analysis showed ECA-binding ability yielding a sensitivity of 85% and specificity of 75%, and a combination of ECA and AFP has better clinical diagnostic efficiency, yielding a sensitivity of 90% and specificity of 85%, than ECA or AFP assay alone. ECA pull-down followed by mass spectrometry further showed that there was significantly less expression of ECA binding membrane catalase (CAT) and prolyl 4-hydroxylase beta polypeptide (P4HB) in HCC tissues compared with the adjacent non-tumor tissues. The abnormally increased expression of total CAT and P4HB and decreased expression of galactosylated membrane CAT and P4HB in HCC cell lines were correlated with an HCC metastasis status. Our findings suggest that abnormal declined ECA-binding galatosylated membrane glycans and two galactosylated-CAT and P4HB glycoproteins in lesion tissues are potential biomarkers in the diagnosis and/or metastasis prediction for HCC.

show abstract

“…There are a limited number of studies in the biosensor field, including PAI. This could be attributed to the tedious process of validating biosensors to determine whether they are clinically applicable and safe for use [ 165 ]. Since the interaction between the probe molecule and the target molecule should be highly selective, i.e., it should not respond adversely to other components in vivo, specifically, if other benign diseases exhibit increased concentrations of the target molecule.…”

Section: Contrast Agents For In Vivo Testingmentioning

confidence: 99%

Exogenous Contrast Agents in Photoacoustic Imaging: An In Vivo Review for Tumor Imaging

et al. 2022

View full text Add to dashboard Cite

The field of cancer theranostics has grown rapidly in the past decade and innovative ‘biosmart’ theranostic materials are being synthesized and studied to combat the fast growth of cancer metastases. While current state-of-the-art oncology imaging techniques have decreased mortality rates, patients still face a diminished quality of life due to treatment. Therefore, improved diagnostics are needed to define in vivo tumor growths on a molecular level to achieve image-guided therapies and tailored dosage needs. This review summarizes in vivo studies that utilize contrast agents within the field of photoacoustic imaging—a relatively new imaging modality—for tumor detection, with a special focus on imaging and transducer parameters. This paper also details the different types of contrast agents used in this novel diagnostic field, i.e., organic-based, metal/inorganic-based, and dye-based contrast agents. We conclude this review by discussing the challenges and future direction of photoacoustic imaging.

show abstract

Lectin-based biosensors as analytical tools for clinical oncology

Cited by 24 publications

References 133 publications

New Templated Ostwald Ripening Process of Mesostructured FeOOH for Third‐Harmonic Generation Bioimaging

New Templated Ostwald Ripening Process of Mesostructured FeOOH for Third‐Harmonic Generation Bioimaging

Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis

Exogenous Contrast Agents in Photoacoustic Imaging: An In Vivo Review for Tumor Imaging

Contact Info

Product

Resources

About